elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33404541-12859B08-CEF1-4238-A199-02EF7A6F244E
Q33404541-12859B08-CEF1-4238-A199-02EF7A6F244E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33404541-12859B08-CEF1-4238-A199-02EF7A6F244E
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
P2860
Q33404541-12859B08-CEF1-4238-A199-02EF7A6F244E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33404541-12859B08-CEF1-4238-A199-02EF7A6F244E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1388965960be21dd3515cb6ab0e9d0be11039d84
P2860
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.